ATE375793T1 - Verwendungen von antikonvulsiven aminosäure zur behandlung bipolarer erkrankungen - Google Patents
Verwendungen von antikonvulsiven aminosäure zur behandlung bipolarer erkrankungenInfo
- Publication number
- ATE375793T1 ATE375793T1 AT04021728T AT04021728T ATE375793T1 AT E375793 T1 ATE375793 T1 AT E375793T1 AT 04021728 T AT04021728 T AT 04021728T AT 04021728 T AT04021728 T AT 04021728T AT E375793 T1 ATE375793 T1 AT E375793T1
- Authority
- AT
- Austria
- Prior art keywords
- lower alkyl
- aryl
- heterocyclic
- unsubstituted
- substituted
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title 1
- 230000002082 anti-convulsion Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 23
- 125000003118 aryl group Chemical group 0.000 abstract 13
- 125000000623 heterocyclic group Chemical group 0.000 abstract 9
- 125000006575 electron-withdrawing group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000003342 alkenyl group Chemical group 0.000 abstract 7
- 125000000304 alkynyl group Chemical group 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 150000002431 hydrogen Chemical group 0.000 abstract 6
- -1 lower Chemical group 0.000 abstract 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- 101100149686 Caenorhabditis elegans snr-4 gene Proteins 0.000 abstract 1
- 101100478234 Caenorhabditis elegans spr-4 gene Proteins 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 239000004593 Epoxy Substances 0.000 abstract 1
- 125000002015 acyclic group Chemical group 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000003838 furazanyl group Chemical group 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000002636 imidazolinyl group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000005956 isoquinolyl group Chemical group 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000003566 oxetanyl group Chemical group 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000005936 piperidyl group Chemical group 0.000 abstract 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000001422 pyrrolinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000005493 quinolyl group Chemical group 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22823000P | 2000-08-25 | 2000-08-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE375793T1 true ATE375793T1 (de) | 2007-11-15 |
Family
ID=22856332
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01966230T ATE357227T1 (de) | 2000-08-25 | 2001-08-24 | Verwendung von aminosäurehältigen antikonvulsiva zur behandlung von schmerz |
| AT04021728T ATE375793T1 (de) | 2000-08-25 | 2001-08-24 | Verwendungen von antikonvulsiven aminosäure zur behandlung bipolarer erkrankungen |
| AT04021727T ATE375792T1 (de) | 2000-08-25 | 2001-08-24 | Verwendung von antikonvulsiven aminosäure zur behandlung von migräne |
| AT06012400T ATE476971T1 (de) | 2000-08-25 | 2001-08-24 | Aminosäure enthaltende antikonvulsiva zur behandlung von zwangsstörungen |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01966230T ATE357227T1 (de) | 2000-08-25 | 2001-08-24 | Verwendung von aminosäurehältigen antikonvulsiva zur behandlung von schmerz |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04021727T ATE375792T1 (de) | 2000-08-25 | 2001-08-24 | Verwendung von antikonvulsiven aminosäure zur behandlung von migräne |
| AT06012400T ATE476971T1 (de) | 2000-08-25 | 2001-08-24 | Aminosäure enthaltende antikonvulsiva zur behandlung von zwangsstörungen |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US6884910B2 (de) |
| EP (5) | EP1486206B1 (de) |
| JP (2) | JP4307068B2 (de) |
| AT (4) | ATE357227T1 (de) |
| AU (6) | AU2001286763C1 (de) |
| CA (2) | CA2419285C (de) |
| CY (5) | CY1107668T1 (de) |
| DE (4) | DE60131033T2 (de) |
| DK (4) | DK1486205T3 (de) |
| ES (5) | ES2294415T3 (de) |
| LU (1) | LU91512I2 (de) |
| PT (4) | PT1695703E (de) |
| WO (1) | WO2002015922A2 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2419285C (en) | 2000-08-25 | 2011-08-02 | Research Corporation Technologies, Inc. | New uses for amino acid anticonvulsants |
| PT1243262E (pt) | 2001-03-20 | 2006-10-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica |
| EP1243263B1 (de) * | 2001-03-21 | 2002-11-27 | Schwarz Pharma Ag | Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen |
| US20040087642A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
| US20050233472A1 (en) * | 2003-09-19 | 2005-10-20 | Kao H P | Spotting high density plate using a banded format |
| ES2325995T3 (es) * | 2003-12-02 | 2009-09-28 | Schwarz Pharma Ag | Nueva utilizacion de compuestos peptidicos para tratamiento del dolor neuropatico central. |
| EP1537862A1 (de) * | 2003-12-02 | 2005-06-08 | Schwarz Pharma Ag | Neue Verwendung von Peptidverbindungen zur Behandlung von zentralen neuropathische-Schmerzen |
| EP1579858A1 (de) * | 2004-03-26 | 2005-09-28 | Schwarz Pharma Ag | Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie |
| JP2007532607A (ja) * | 2004-04-16 | 2007-11-15 | シュバルツ ファルマ アクチェンゲゼルシャフト | 慢性頭痛の予防及び治療のためのペプチド化合物の使用 |
| EP1604654A1 (de) * | 2004-05-18 | 2005-12-14 | Schwarz Pharma Ag | Neue Verwendung von Peptidverbindungen zur Behandlung von Dyskynesien |
| EP1604655A1 (de) * | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie |
| US7427601B2 (en) | 2004-06-24 | 2008-09-23 | Schwarz Pharma Ag | Method for treating tremor |
| EP1629839A1 (de) * | 2004-08-27 | 2006-03-01 | Schwarz Pharma Ag | Verwendung von Peptidverbindungen zur Behandlung von Knochenkrebsschmerz sowie von Chemotherapie- oder Nukleosid-induziertem Schmerz |
| BRPI0514721A (pt) * | 2004-08-27 | 2008-06-24 | Sanol Arznei Schwarz Gmbh | uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo |
| US20060252749A1 (en) * | 2005-01-28 | 2006-11-09 | Srz Properties, Inc. | Lacosamide for add-on therapy of psychosis |
| EP1754476A1 (de) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| ES2531118T5 (es) | 2006-06-15 | 2022-06-14 | Ucb Pharma Gmbh | Composición farmacéutica que comprende lacosamida y levetiracetamo para uso en el tratamiento de la epilepsia |
| EP1920780A1 (de) * | 2006-10-12 | 2008-05-14 | Schwarz Pharma Ag | Peptidverbindungen zur Behandlung von Krankheiten mit erhöhter Erregbarkeit |
| CN101466390B (zh) * | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
| US7489198B1 (en) | 2007-04-26 | 2009-02-10 | Lockheed Martin Corporation | Linear regulating switch |
| WO2011101863A2 (en) | 2010-02-19 | 2011-08-25 | Cadila Healthcare Limited | Extended release pharmaceutical compositions of lacosamide |
| WO2015200322A1 (en) * | 2014-06-23 | 2015-12-30 | Northwestern University | Methods of treating or ameliorating migraine |
| KR102686169B1 (ko) | 2015-11-03 | 2024-07-19 | 킴벌리-클라크 월드와이드, 인크. | 고 벌크 및 저 린트를 갖는 페이퍼 티슈 |
| BR112019021283B1 (pt) | 2017-04-28 | 2023-02-28 | Kimberly-Clark Worldwide, Inc | Método para produzir um substrato, e, substrato |
| AU2017441040B2 (en) | 2017-11-29 | 2023-12-21 | Kimberly-Clark Worldwide, Inc. | Fibrous sheet with improved properties |
| KR102299453B1 (ko) | 2018-07-25 | 2021-09-08 | 킴벌리-클라크 월드와이드, 인크. | 3차원 폼-레이드 부직포 제조 공정 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE795788A (nl) * | 1972-02-22 | 1973-08-22 | Akzo Nv | Werkwijze ter bereiding van peptiden en peptide-derivaten en de toepassing hiervan |
| US4533657A (en) * | 1981-07-24 | 1985-08-06 | Sterling Drug Inc. | Analgesic dipeptide amides and method of use and composition thereof |
| US4510082A (en) * | 1983-03-07 | 1985-04-09 | Eli Lilly And Company | Pharmacologically active peptides |
| FR2546517B1 (fr) * | 1983-05-24 | 1987-04-24 | Panmedica | Nouveaux dipeptides du -l-5-hydroxy-tryptophane, procedes pour leur preparation et medicaments les contenant |
| JPH0680079B2 (ja) * | 1984-11-09 | 1994-10-12 | エーザイ株式会社 | ポリペプチド |
| US5654301A (en) * | 1985-02-15 | 1997-08-05 | Research Corporation Technologies, Inc. | Amino acid derivative anticonvulsant |
| US5378729A (en) | 1985-02-15 | 1995-01-03 | Research Corporation Technologies, Inc. | Amino acid derivative anticonvulsant |
| US5728680A (en) * | 1987-12-30 | 1998-03-17 | Cytoven J.V. | Methods for normalizing numbers of lymphocytes |
| US5331089A (en) * | 1988-03-25 | 1994-07-19 | Merck Sharpe & Dohme, Ltd. | Peptides useful as tachykinin agonists |
| US5178729A (en) * | 1991-01-15 | 1993-01-12 | James River Corporation Of Virginia | High purity stratified tissue and method of making same |
| US5854217A (en) * | 1992-09-28 | 1998-12-29 | Bearsden Bio, Inc. | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| WO1994017794A1 (en) | 1993-02-03 | 1994-08-18 | Steven Andrew Jennings | Blends of glycine derivatives and sugars |
| DE59409631D1 (de) * | 1993-07-15 | 2001-02-15 | Hoffmann La Roche | Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält |
| GB9318637D0 (en) * | 1993-09-08 | 1993-10-27 | Ferring Res Ltd | Enzyme inhibitors |
| US5508266A (en) * | 1994-06-22 | 1996-04-16 | Ciba-Geigy Corporation | Gem-disubstituted amino acid derivatives |
| US6348571B1 (en) * | 1994-09-12 | 2002-02-19 | Northwestern University | Corticotropin release inhibiting factor and methods of using same |
| CZ288436B6 (en) * | 1994-10-05 | 2001-06-13 | Darwin Discovery Ltd | Peptidyl derivatives, their therapeutic use as inhibitors of metalloproteinases and pharmaceutical preparation in which they are comprised |
| US5798337A (en) * | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
| US5780589A (en) * | 1994-11-30 | 1998-07-14 | The United States Of America As Represented By The Department Of Health And Human Services | Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof |
| US6037324A (en) * | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| GB9601724D0 (en) | 1996-01-29 | 1996-03-27 | Merck Sharp & Dohme | Therapeutic agents |
| US5773475A (en) * | 1997-03-17 | 1998-06-30 | Research Corporation Technologies, Inc. | Anticonvulsant enantiomeric amino acid derivatives |
| US6126939A (en) * | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| US6514937B1 (en) * | 1997-02-25 | 2003-02-04 | Celtrix Pharmaceuticals, Inc. | Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 |
| US6197746B1 (en) * | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
| KR100522012B1 (ko) | 1997-07-08 | 2005-10-18 | 오노 야꾸힝 고교 가부시키가이샤 | 아미노산 유도체 |
| AU7937298A (en) | 1997-07-08 | 1999-02-08 | Ono Pharmaceutical Co. Ltd. | Amino acid derivatives |
| AU744899B2 (en) | 1997-07-15 | 2002-03-07 | Research Corporation Technologies, Inc. | Amino acid derivatives useful to treat stroke |
| US6737408B1 (en) * | 1997-08-07 | 2004-05-18 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
| US6028102A (en) * | 1998-02-24 | 2000-02-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anticonvulsant drugs and pharmaceutical compositions thereof |
| US6228875B1 (en) | 1998-04-14 | 2001-05-08 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
| ES2262322T3 (es) | 1998-06-10 | 2006-11-16 | Meiji Seika Kaisha, Ltd. | Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar. |
| US6716810B1 (en) * | 1998-12-09 | 2004-04-06 | Eleanor Roosevelt Institute | Composition and method for regulation of body weight and associated conditions |
| US6399574B1 (en) * | 2000-03-22 | 2002-06-04 | University Of Utah Research Foundation | Use of conantokins |
| CA2419285C (en) * | 2000-08-25 | 2011-08-02 | Research Corporation Technologies, Inc. | New uses for amino acid anticonvulsants |
| US6228825B1 (en) | 2000-10-13 | 2001-05-08 | Colgate Palmolive Company | Automatic dishwashing cleaning system |
| PT1243262E (pt) * | 2001-03-20 | 2006-10-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica |
-
2001
- 2001-08-24 CA CA2419285A patent/CA2419285C/en not_active Expired - Fee Related
- 2001-08-24 ES ES04021728T patent/ES2294415T3/es not_active Expired - Lifetime
- 2001-08-24 AT AT01966230T patent/ATE357227T1/de active
- 2001-08-24 ES ES01966230T patent/ES2281439T3/es not_active Expired - Lifetime
- 2001-08-24 AT AT04021728T patent/ATE375793T1/de active
- 2001-08-24 PT PT06012400T patent/PT1695703E/pt unknown
- 2001-08-24 DE DE60131033T patent/DE60131033T2/de not_active Expired - Lifetime
- 2001-08-24 EP EP04021728A patent/EP1486206B1/de not_active Expired - Lifetime
- 2001-08-24 CA CA2740815A patent/CA2740815C/en not_active Expired - Fee Related
- 2001-08-24 PT PT01966230T patent/PT1365787E/pt unknown
- 2001-08-24 ES ES04021727T patent/ES2294414T3/es not_active Expired - Lifetime
- 2001-08-24 AT AT04021727T patent/ATE375792T1/de active
- 2001-08-24 JP JP2002520843A patent/JP4307068B2/ja not_active Expired - Fee Related
- 2001-08-24 PT PT04021728T patent/PT1486206E/pt unknown
- 2001-08-24 AU AU2001286763A patent/AU2001286763C1/en not_active Ceased
- 2001-08-24 EP EP04021727A patent/EP1486205B1/de not_active Expired - Lifetime
- 2001-08-24 DE DE60127459T patent/DE60127459T2/de not_active Expired - Lifetime
- 2001-08-24 DK DK04021727T patent/DK1486205T3/da active
- 2001-08-24 EP EP10160637.4A patent/EP2210598B1/de not_active Expired - Lifetime
- 2001-08-24 DE DE60142806T patent/DE60142806D1/de not_active Expired - Lifetime
- 2001-08-24 US US09/938,677 patent/US6884910B2/en not_active Expired - Lifetime
- 2001-08-24 AT AT06012400T patent/ATE476971T1/de active
- 2001-08-24 AU AU8676301A patent/AU8676301A/xx active Pending
- 2001-08-24 ES ES06012400T patent/ES2348646T3/es not_active Expired - Lifetime
- 2001-08-24 DK DK04021728T patent/DK1486206T3/da active
- 2001-08-24 ES ES10160637T patent/ES2435000T3/es not_active Expired - Lifetime
- 2001-08-24 WO PCT/US2001/026568 patent/WO2002015922A2/en not_active Ceased
- 2001-08-24 DK DK06012400.5T patent/DK1695703T3/da active
- 2001-08-24 DE DE60131032T patent/DE60131032T2/de not_active Expired - Lifetime
- 2001-08-24 DK DK01966230T patent/DK1365787T3/da active
- 2001-08-24 PT PT04021727T patent/PT1486205E/pt unknown
- 2001-08-24 EP EP01966230A patent/EP1365787B1/de not_active Expired - Lifetime
- 2001-08-24 EP EP06012400A patent/EP1695703B1/de not_active Expired - Lifetime
-
2003
- 2003-10-17 US US10/688,709 patent/US7186859B2/en not_active Expired - Fee Related
- 2003-10-17 US US10/688,638 patent/US7148378B2/en not_active Expired - Lifetime
-
2007
- 2007-01-10 US US11/651,845 patent/US7772427B2/en not_active Expired - Fee Related
- 2007-05-23 AU AU2007202336A patent/AU2007202336B9/en not_active Ceased
- 2007-06-11 CY CY20071100768T patent/CY1107668T1/el unknown
-
2008
- 2008-01-11 CY CY20081100041T patent/CY1107853T1/el unknown
- 2008-01-11 CY CY20081100040T patent/CY1107852T1/el unknown
- 2008-11-28 JP JP2008304255A patent/JP5190334B2/ja not_active Expired - Fee Related
-
2009
- 2009-01-14 LU LU91512C patent/LU91512I2/fr unknown
- 2009-02-18 CY CY200900002C patent/CY2009002I2/el unknown
- 2009-06-12 AU AU2009202362A patent/AU2009202362B2/en not_active Ceased
- 2009-06-12 AU AU2009202363A patent/AU2009202363B2/en not_active Ceased
-
2010
- 2010-07-01 US US12/829,160 patent/US8519183B2/en not_active Expired - Fee Related
- 2010-11-04 CY CY20101101002T patent/CY1112349T1/el unknown
-
2011
- 2011-05-17 AU AU2011202293A patent/AU2011202293B2/en not_active Ceased
-
2013
- 2013-07-29 US US13/953,213 patent/US20130316953A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE375793T1 (de) | Verwendungen von antikonvulsiven aminosäure zur behandlung bipolarer erkrankungen | |
| EA200601799A1 (ru) | Гидразидсодержащие соединения - ингибиторы cftr и их применение | |
| AR061743A1 (es) | Compuestos peptidicos para el tratamiento de trastornos de hiperexcitabilidad y trastornos asociados con disfuncion del canal de hierro | |
| JP2007530493A5 (de) | ||
| JP2009545521A5 (de) | ||
| AR061475A1 (es) | Compuestos peptidicos para tratar status epilepticus refractario | |
| IS8058A (is) | Sýklísk súlfónamíð til að hamla gamma seytiasa | |
| JP2008501760A5 (de) | ||
| JP2008501753A5 (de) | ||
| KR970706818A (ko) | 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide) | |
| BR0008365A (pt) | 2-amino-6-anilino-purinas e o seu uso comomedicamento | |
| JP2007532607A5 (de) | ||
| JP2008510758A5 (de) | ||
| ATE305469T1 (de) | Sulfonsäure- oder sulfonylamino-n-(heteroaralkyl)-azaheterozyklyl midverbindungen | |
| EP1274414A4 (de) | Nasale verabreichung von mitteln zur behandlung von gastroparese | |
| DE602004031631D1 (de) | Verwendung von betain zur behandlung von claudicatio intermittens | |
| EA200501549A1 (ru) | Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца | |
| ATE260655T1 (de) | Verwendung von stickstoffhaltigen aromatischen heterozyklusderivaten zur topischen behandlung von epithelerkrankungen | |
| DE69924979D1 (de) | Behandlung von chronischen schmerzen | |
| TR200103561T2 (tr) | Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları | |
| TR200103562T2 (tr) | Amiloid proteini toplanmasını önleme ve amiloid birikintilerini görüntüleme yönteminde kullanım için rodanin türevleri | |
| ATE423564T1 (de) | Zusammensetzung für die kosmetische behandlung von altersbedingten dermatologischen symptomen | |
| DE60127571D1 (de) | Tiagabine zur behandlung von diabetischer neuropathie | |
| ATE288254T1 (de) | Methode zur behandlung von schlaganfall | |
| AR050097A1 (es) | Uso de compuestos peptidicos para tratar dolor en neuropatia diabetica dolorosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1486206 Country of ref document: EP |